Drug Target Review – Issue 2 2021

Posted: 14 June 2021 | | No comments yet

This issue includes articles on novel AAV vectors to deliver ocular gene therapy, how phenotypic models of disease are being used in covalent fragment screening and the challenges and opportunities presented by automation in the life sciences. Also in this issue are features on stem cells, antibodies and hit-to-lead. 

DTR Issue 2 2021

Included in this issue:

    The potential of epigenomic medicine in cardiology
    Professor John Giannios, Learna
    Using cholangiocyte organoids to regenerate human bile ducts
    Dr Fotios Sampaziotis, University of Cambridge
    Making cell culture models more physiologically relevant
    Robert Skolik, University of Louisville
    Transcriptional reprogramming rescues vascular fate of misidentified pluripotent cell-derived epithelial cells
    Dr Raphaël Lis, Weill Cornell Medicine
    Screening for COVID-19 drugs
    Professor Arvind Patel, Medical Research Council-University of Glasgow Centre for Virus Research (CVR) 
    How to mix the best anti-SARS-CoV-2 cocktail
    Dr Zhiqiang Ku, University of Texas Health Science Center at Houston

The rest of this content is restricted - login or subscribe free to access

Screening the future innovations in drug discoveryThank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.

Why subscribe? Join our growing community of thousands of industry professionals and gain access to:

  • quarterly issues in print and/or digital format
  • case studies, whitepapers, webinars and industry-leading content
  • breaking news and features
  • our extensive online archive of thousands of articles and years of past issues
  • ...And it's all free!

Click here to Subscribe today Login here